Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;37(1):155-199.
doi: 10.1007/s12325-019-01163-6. Epub 2019 Dec 10.

Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review

Marcelo Luís Occhiutto  1 , Raul C Maranhão  2   3 , Vital Paulino Costa  1 , Anastasios G Konstas  4
Affiliations
Review

Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review

Marcelo Luís Occhiutto et al. Adv Ther. 2020 Jan.

Abstract

Glaucoma is the second leading cause of blindness worldwide. Even though significant advances have been made in its management, currently available antiglaucoma therapies suffer from considerable drawbacks. Typically, the success and efficacy of glaucoma medications are undermined by their limited bioavailability to target tissues and the inadequate adherence demonstrated by patients with glaucoma. The latter is due to a gradual decrease in tolerability of lifelong topical therapies and the significant burden to patients of prescribed stepwise antiglaucoma regimens with frequent dosing which impact quality of life. On the other hand, glaucoma surgery is restricted by the inability of antifibrotic agents to efficiently control the wound healing process without causing severe collateral damage and long-term complications. Evolution of the treatment paradigm for patients with glaucoma will ideally include prevention of retinal ganglion cell degeneration by the successful delivery of neurotrophic factors, anti-inflammatory drugs, and gene therapies. Nanotechnology-based treatments may surpass the limitations of currently available glaucoma therapies through optimized targeted drug delivery, increased bioavailability, and controlled release. This review addresses the recent advances in glaucoma treatment strategies employing nanotechnology, including medical and surgical management, neuroregeneration, and neuroprotection.

Keywords: Glaucoma; Nanomedicine; Nanoparticles; Nanosystems; Nanotechnology; Ocular drug delivery; Ophthamlology.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Glaucoma therapeutic strategies and nanotechnology-based potential applications
Fig. 2
Fig. 2
Schematic depiction of some nanoparticles
See this image and copyright information in PMC

References

    1. Thylefors B, Négrel AD. The global impact of glaucoma. Bull World Health Organ. 1994;72(3):323–326. - PMC - PubMed
    1. Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844–851. - PMC - PubMed
    1. WHO. The global impact of glaucoma. Bull World Health Organ. 1994;72(3):323–6. http://www.who.int/blindness/publications/glaucoma/en/. Accessed 7 Dec 2019. - PMC - PubMed
    1. Stein JD, Lee PP. Screening for glaucoma. In: Yanoff M, Duker JS, editors. Ophthalmology. Amsterdan, The Netherlands: Elsevier Sanders; 2009. p. 1007.
    1. Heiji A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279. - PubMed

Publication types